0001209191-20-006846.txt : 20200205
0001209191-20-006846.hdr.sgml : 20200205
20200205160518
ACCESSION NUMBER: 0001209191-20-006846
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200203
FILED AS OF DATE: 20200205
DATE AS OF CHANGE: 20200205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROSS ROBERT W.
CENTRAL INDEX KEY: 0001733077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38459
FILM NUMBER: 20578751
MAIL ADDRESS:
STREET 1: C/O SURFACE ONCOLOGY
STREET 2: 50 HAMPSHIRE ST., 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Surface Oncology, Inc.
CENTRAL INDEX KEY: 0001718108
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-714-4096
MAIL ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-03
0
0001718108
Surface Oncology, Inc.
SURF
0001733077
ROSS ROBERT W.
C/O SURFACE ONCOLOGY, INC.
50 HAMPSHIRE STREET, 8TH FLOOR
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2020-02-03
4
A
0
80000
0.00
A
105000
D
Stock Option (Right to Buy)
3.18
2020-02-03
4
A
0
80000
0.00
A
2030-02-03
Common Stock
80000
80000
D
The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or
other service provider of the Company on such date.
This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates.
/s/ Jessica Fees, as Attorney-in-Fact
2020-02-05